![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LAMTOR2 |
Gene summary for LAMTOR2 |
![]() |
Gene information | Species | Human | Gene symbol | LAMTOR2 | Gene ID | 28956 |
Gene name | late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 | |
Gene Alias | ENDAP | |
Cytomap | 1q22 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9Y2Q5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28956 | LAMTOR2 | GSM4909285 | Human | Breast | IDC | 3.63e-21 | 5.14e-01 | 0.21 |
28956 | LAMTOR2 | GSM4909287 | Human | Breast | IDC | 2.63e-06 | 3.96e-01 | 0.2057 |
28956 | LAMTOR2 | GSM4909291 | Human | Breast | IDC | 1.40e-05 | 4.20e-01 | 0.1753 |
28956 | LAMTOR2 | GSM4909293 | Human | Breast | IDC | 2.73e-11 | 4.16e-01 | 0.1581 |
28956 | LAMTOR2 | GSM4909294 | Human | Breast | IDC | 3.19e-08 | 4.02e-01 | 0.2022 |
28956 | LAMTOR2 | GSM4909296 | Human | Breast | IDC | 6.32e-12 | 3.49e-01 | 0.1524 |
28956 | LAMTOR2 | GSM4909297 | Human | Breast | IDC | 1.49e-04 | -1.01e-01 | 0.1517 |
28956 | LAMTOR2 | GSM4909302 | Human | Breast | IDC | 4.44e-09 | 4.07e-01 | 0.1545 |
28956 | LAMTOR2 | GSM4909304 | Human | Breast | IDC | 2.94e-07 | 3.95e-01 | 0.1636 |
28956 | LAMTOR2 | GSM4909306 | Human | Breast | IDC | 7.49e-12 | 4.96e-01 | 0.1564 |
28956 | LAMTOR2 | GSM4909307 | Human | Breast | IDC | 5.07e-10 | 4.63e-01 | 0.1569 |
28956 | LAMTOR2 | GSM4909308 | Human | Breast | IDC | 1.01e-28 | 6.53e-01 | 0.158 |
28956 | LAMTOR2 | GSM4909311 | Human | Breast | IDC | 8.61e-26 | 2.63e-02 | 0.1534 |
28956 | LAMTOR2 | GSM4909312 | Human | Breast | IDC | 3.57e-10 | 2.24e-01 | 0.1552 |
28956 | LAMTOR2 | GSM4909313 | Human | Breast | IDC | 4.83e-03 | 1.70e-01 | 0.0391 |
28956 | LAMTOR2 | GSM4909315 | Human | Breast | IDC | 8.04e-08 | 4.36e-01 | 0.21 |
28956 | LAMTOR2 | GSM4909316 | Human | Breast | IDC | 1.56e-05 | 3.77e-01 | 0.21 |
28956 | LAMTOR2 | GSM4909317 | Human | Breast | IDC | 2.69e-04 | 3.36e-01 | 0.1355 |
28956 | LAMTOR2 | GSM4909318 | Human | Breast | IDC | 4.48e-07 | 5.21e-01 | 0.2031 |
28956 | LAMTOR2 | GSM4909319 | Human | Breast | IDC | 5.04e-34 | -1.01e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004320013 | Oral cavity | LP | response to amino acid | 41/4623 | 116/18723 | 6.57e-03 | 3.85e-02 | 41 |
GO:015011518 | Oral cavity | LP | cell-substrate junction organization | 36/4623 | 101/18723 | 8.98e-03 | 4.83e-02 | 36 |
GO:015011515 | Prostate | BPH | cell-substrate junction organization | 49/3107 | 101/18723 | 9.49e-14 | 1.01e-11 | 49 |
GO:001604910 | Prostate | BPH | cell growth | 139/3107 | 482/18723 | 7.53e-12 | 5.90e-10 | 139 |
GO:015011615 | Prostate | BPH | regulation of cell-substrate junction organization | 35/3107 | 71/18723 | 1.81e-10 | 1.02e-08 | 35 |
GO:000155810 | Prostate | BPH | regulation of cell growth | 116/3107 | 414/18723 | 2.66e-09 | 1.05e-07 | 116 |
GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
GO:00434106 | Prostate | BPH | positive regulation of MAPK cascade | 110/3107 | 480/18723 | 1.81e-04 | 1.53e-03 | 110 |
GO:00107617 | Prostate | BPH | fibroblast migration | 17/3107 | 47/18723 | 9.41e-04 | 5.94e-03 | 17 |
GO:00011018 | Prostate | BPH | response to acid chemical | 37/3107 | 135/18723 | 1.03e-03 | 6.46e-03 | 37 |
GO:19024143 | Prostate | BPH | protein localization to cell junction | 27/3107 | 94/18723 | 2.25e-03 | 1.24e-02 | 27 |
GO:00712294 | Prostate | BPH | cellular response to acid chemical | 23/3107 | 80/18723 | 4.53e-03 | 2.19e-02 | 23 |
GO:00712303 | Prostate | BPH | cellular response to amino acid stimulus | 20/3107 | 71/18723 | 9.89e-03 | 4.16e-02 | 20 |
GO:015011516 | Prostate | Tumor | cell-substrate junction organization | 46/3246 | 101/18723 | 4.27e-11 | 2.82e-09 | 46 |
GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
GO:015011616 | Prostate | Tumor | regulation of cell-substrate junction organization | 34/3246 | 71/18723 | 2.86e-09 | 1.18e-07 | 34 |
GO:000166718 | Prostate | Tumor | ameboidal-type cell migration | 130/3246 | 475/18723 | 2.36e-08 | 8.09e-07 | 130 |
GO:000155815 | Prostate | Tumor | regulation of cell growth | 115/3246 | 414/18723 | 6.40e-08 | 1.88e-06 | 115 |
GO:004341012 | Prostate | Tumor | positive regulation of MAPK cascade | 110/3246 | 480/18723 | 9.41e-04 | 6.18e-03 | 110 |
GO:000110114 | Prostate | Tumor | response to acid chemical | 38/3246 | 135/18723 | 1.19e-03 | 7.56e-03 | 38 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04150 | Colorectum | MSS | mTOR signaling pathway | 47/1875 | 156/8465 | 1.19e-02 | 3.99e-02 | 2.44e-02 | 47 |
hsa041501 | Colorectum | MSS | mTOR signaling pathway | 47/1875 | 156/8465 | 1.19e-02 | 3.99e-02 | 2.44e-02 | 47 |
hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LAMTOR2 | SNV | Missense_Mutation | c.46N>G | p.Thr16Ala | p.T16A | Q9Y2Q5 | protein_coding | deleterious(0) | possibly_damaging(0.449) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
LAMTOR2 | insertion | Nonsense_Mutation | novel | c.297_298insAATAACATCACTCATTTGGACAACTGTTGGCAGATATGAAATTTCAT | p.Gly100AsnfsTer13 | p.G100Nfs*13 | Q9Y2Q5 | protein_coding | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | ||
LAMTOR2 | SNV | Missense_Mutation | c.177C>G | p.Asn59Lys | p.N59K | Q9Y2Q5 | protein_coding | deleterious(0.03) | possibly_damaging(0.51) | TCGA-CM-4747-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | fluorouracil | SD | |
LAMTOR2 | SNV | Missense_Mutation | c.97G>T | p.Ala33Ser | p.A33S | Q9Y2Q5 | protein_coding | deleterious(0.03) | benign(0.39) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
LAMTOR2 | SNV | Missense_Mutation | novel | c.215T>C | p.Ile72Thr | p.I72T | Q9Y2Q5 | protein_coding | deleterious(0.01) | possibly_damaging(0.873) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LAMTOR2 | SNV | Missense_Mutation | novel | c.178G>T | p.Gly60Trp | p.G60W | Q9Y2Q5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
LAMTOR2 | SNV | Missense_Mutation | c.298G>T | p.Gly100Cys | p.G100C | Q9Y2Q5 | protein_coding | tolerated(0.06) | benign(0.088) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
LAMTOR2 | SNV | Missense_Mutation | c.284C>A | p.Ala95Asp | p.A95D | Q9Y2Q5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-33-4583-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LAMTOR2 | SNV | Missense_Mutation | c.152A>C | p.Asn51Thr | p.N51T | Q9Y2Q5 | protein_coding | deleterious(0) | possibly_damaging(0.749) | TCGA-66-2785-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LAMTOR2 | insertion | Frame_Shift_Ins | novel | c.308_309insA | p.Met103IlefsTer37 | p.M103Ifs*37 | Q9Y2Q5 | protein_coding | TCGA-66-2763-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |